RG
NGM

Redmile Group’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Redmile Group’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-582,805
Closed -$10.3M – 73
2021
Q4 		$10.3M Sell
582,805
-1,922,313
-77% -$36.9M 0.23% 60
2021
Q3 		$52.7M Sell
2,505,118
-287,330
-10% -$6.33M 0.92% 34
2021
Q2 		$55.1M Buy
2,792,448
+40,633
+1% +$951K 0.81% 38
2021
Q1 		$80M Buy
+2,751,815
New +$77M 1.13% 29

Other funds holding NGM

CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Redmile Group's NGM Position: Q1 2022 in Review

Redmile Group sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2022, closing a stake of 582,805 shares — an estimated $10.3M sold.

Redmile Group first reported a position in NGM in Q1 2021 and held it in 4 quarters. The position peaked at $80M in Q1 2021. 114 funds tracked by Wall St. Rank hold NGM as of Q1 2022.

  • Redmile Group reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Redmile Group sold 582,805 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $10.3M.
  • Redmile Group first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • Redmile Group's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $80M in Q1 2021.
  • 114 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on Redmile Group's 13F filing for Q1 2022, filed 16 May 2022.